Naturally Splendid (TSXV:NSP) (OTCQB:NSPDF) (Frankfurt:50N) (“Naturally Splendid” or “NSE” or “The Company”) is pleased to appoint Dr. Lorne Swetlikoff BSc., ND to its Advisory Board as Medical Advisor.

Dr. Lorne Swetlikoff, BSc., ND, is a licensed Naturopathic Physician (Bastyr University of Naturopathic Medicine in Seattle) with a Bachelor of Science Degree in Cell and Development Biology from UBC. Dr. Swetlikoff has been in practice for 24 years and has extensive experience in comprehensive patient care and naturopathic medicine through his clinics in Vancouver and Castlegar. He currently owns and operates Vancouver Naturopathic Clinic a busy, progressive and successful naturopathic practice in Vancouver.


In addition to his clinical practice, Dr. Swetlikoff served as the President of the College of Naturopathic Physicians of British Columbia from 2002 – 2011. Under the leadership of Dr. Swetlikoff, the College was able to work with the provincial government and multi-health care party negotiations to achieve ground-breaking changes in the naturopathic medical scope of practice. Naturopathic physicians in BC enjoy one of the broadest scopes of practice in North America and now have prescribing authority for conventional drugs and natural substances requiring a prescription, due in part to the efforts of Dr. Swetlikoff.

Naturally Splendid Executive Vice President of Marketing & Innovation Bryan Carson states, “I would like to personally welcome Dr. Swetlikoff to the Naturally Splendid Team in general and even more significantly, to the position of Medical Advisor, whose role will include the continued development of the NATERA FX line of products and distribution channels. It is an immense honour to have Dr. Swetlikoff endorse our recently launched NATERA FX line of practitioner grade, hemp-based, therapeutic healthcare products”.

Dr. Swetlikoff states, “It has been a pleasure to observe the development of the NATERA FX(TM) therapeutic line and to witness the commitment to quality that has been insisted upon. This will be the first appointment of this kind that I have accepted and it is due in large part to the quality of product Naturally Splendid has insisted upon, in combination with being on the cutting edge of product development in the area of hemp and cannabinoid extraction specifically for the healthcare practitioner market. I look forward to several more equally as successful product launches as the recent launch at the British Columbia Naturopathic Association’s (BCNA’s) Advancing Naturopathic Medicine 2018 Exhibition in Vancouver recently, that I was an active participant in”.

Dr. Swetlikoff values continuous education in the field of medicine and holds many special certifications in alternative health treatments such as anti-aging therapy, chelation therapy, neural therapy, orthomolecular therapy,
ozone therapy and many other diploma and certificate programs in diagnosis and treatment technologies. Dr. Swetlikoff is an active professional member with leading professional medical organizations including American College for Advancement in Medicine, American Academy of Anti-Aging Medicine, Institute For Functional Medicine, and the Occidental Institute.

Industry officials and peers have acknowledged Dr. Swetlikoff as a leader in the field of naturopathic medicine. Dr. Swetlikoff has written for various newspapers including CBC Health Online, and is a respected lecturer and speaker on alternative health care in Canada.

About Naturally Splendid Enterprises Ltd.

Naturally Splendid is a biotechnology and consumer products company that is developing, producing, commercializing, and licensing an entirely new generation of plant-derived, bioactive ingredients, nutrient dense foods, and related products. Naturally Splendid is building an expanding portfolio of patents (issued and pending) and proprietary intellectual property focused on the commercial uses of industrial hemp and marijuana cannabinoid compounds in a broad spectrum of applications.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-673-9573

On Behalf of the Board of Directors

Mr. Douglas Mason

CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.

(NSP – TSX Venture; NSPDF – OTCQB; 50N Frankfurt)

#108-19100 Airport Way

Pitt Meadows, BC, V3Y 0E2

Office: (604) 465-0548

Fax: (604) 465-1128

E-mail: info@naturallysplendid.com

Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid’s control including, Naturally Splendid’s ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Click here to connect with Naturally Splendid (TSXV:NSP) for an Investor Presentation.

Source: www.thenewswire.com

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less

Part of “Rooted in Good” CSR Platform, “Feed the Block” Gives Back Through Strategic Social Partnerships with Local Organizations Focused on Food Insecurity

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced a multi-state fundraising initiative in which proceeds will benefit 24 locally run food banks, homeless shelters and nonprofits working to proactively address the needs of those facing food insecurity in communities across America. This effort is a part of the Strategic Social Partnerships pillar within Curaleaf’s “Rooted in Good” Corporate Social Responsibility platform.

Keep reading... Show less

On September 8, 2020, Aurora Cannabis Inc. (NYSE:ACB) stunned the market when it announced that it expected to record up to $1.8 billion in goodwill impairment charges in the fourth quarter of 2020. On the same day, Aurora also announced a charge of approximately $140 million in the carrying value of certain inventory, and that it was appointing a new chief executive officer. On this news, Aurora’s stock fell approximately 11.6% in just one day. Since May 2020, Aurora’s stock is down approximately $10.00 per share

A lawsuit alleging violations of federal securities laws has been filed against Aurora and certain of its officers and directors. The suit alleges, among other things, that Aurora misled investors as to the value of prior acquisitions, that the Company had experienced degradation in certain assets, and that as a result, it was foreseeable that Aurora would record significant goodwill and asset impairment charges. According to the lawsuit, this news was so shocking because Aurora had previously lauded a “business transformation plan” that would purportedly “better align the business financially with the current realities of the cannabis market.”

Keep reading... Show less

  • Exclusive patent licensed from University of Idaho.
  • Mustard-derived fumigation of stored food – targeting vegetables and potatoes.
  • Leading agrochemical for sprout suppression – chlorpropham – banned by European Union on Oct. 8, 2020.
  • Appointment of Scientific Advisor Dr. Matthew J. Morra, professor emeritus of soil biochemistry at University of Idaho.

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce the exclusive patent licensing from the University of Idaho pertaining to a natural biopesticide mustard-based treatment of stored produce and other foods, particularly sprout suppression of potatoes.

Keep reading... Show less